BioXcel Therapeutics Ownership
| BTAI Stock | USD 0.41 0.04 8.89% |
Shares in Circulation | First Issued 2017-03-31 | Previous Quarter 40.3 M | Current Value 42.4 M | Avarage Shares Outstanding 23.1 M | Quarterly Volatility 7.8 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
BioXcel |
BioXcel Stock Ownership Analysis
About 20.0% of the company shares are held by company insiders. The company recorded a loss per share of 2.04. BioXcel Therapeutics had not issued any dividends in recent years. BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut. Bioxcel Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 89 people. For more info on BioXcel Therapeutics please contact Vimal Mehta at 475 238 6837 or go to https://www.bioxceltherapeutics.com.Besides selling stocks to institutional investors, BioXcel Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different BioXcel Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align BioXcel Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
BioXcel Therapeutics Quarterly Liabilities And Stockholders Equity |
|
About 20.0% of BioXcel Therapeutics are currently held by insiders. Unlike BioXcel Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against BioXcel Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of BioXcel Therapeutics' insider trades
BioXcel Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as BioXcel Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading BioXcel Therapeutics backward and forwards among themselves. BioXcel Therapeutics' institutional investor refers to the entity that pools money to purchase BioXcel Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Goldman Sachs Group Inc | 2024-06-30 | 99 K | Bank Of America Corp | 2024-06-30 | 73.4 K | Virtu Financial Llc | 2024-06-30 | 57.3 K | Hrt Financial Llc | 2024-06-30 | 53 K | Ubs Group Ag | 2024-06-30 | 52.5 K | Arete Wealth Advisors, Llc | 2024-06-30 | 43.5 K | Northern Trust Corp | 2024-09-30 | 40.7 K | Hennion & Walsh Asset Management Inc | 2024-09-30 | 40.1 K | Diversify Wealth Management, Llc | 2024-06-30 | 40 K | Vanguard Group Inc | 2024-09-30 | 1.2 M | Blackrock Inc | 2024-06-30 | 440.7 K |
BioXcel Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific BioXcel Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on BioXcel Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases BioXcel Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
BioXcel Therapeutics Outstanding Bonds
BioXcel Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. BioXcel Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most BioXcel bonds can be classified according to their maturity, which is the date when BioXcel Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Currently Active Assets on Macroaxis
When determining whether BioXcel Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioXcel Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bioxcel Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bioxcel Therapeutics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioXcel Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in BioXcel Stock please use our How to Invest in BioXcel Therapeutics guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioXcel Therapeutics. If investors know BioXcel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioXcel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.04) | Revenue Per Share 0.074 | Quarterly Revenue Growth 1.416 | Return On Assets (0.64) | Return On Equity (17.67) |
The market value of BioXcel Therapeutics is measured differently than its book value, which is the value of BioXcel that is recorded on the company's balance sheet. Investors also form their own opinion of BioXcel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is BioXcel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioXcel Therapeutics' market value can be influenced by many factors that don't directly affect BioXcel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioXcel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioXcel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioXcel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.